Advanced Cholesterol Testing Beyond Standard Lipid Panel and ApoB
The most clinically useful advanced cholesterol test beyond the standard lipid panel and apoB is lipoprotein(a) [Lp(a)], which should be measured once in patients with familial risk, premature atherosclerosis, or unexplained cardiovascular events, with levels ≥50 mg/dL or ≥125 nmol/L considered a risk-enhancing factor. 1
Primary Recommendation: Non-HDL-C First
Before pursuing expensive advanced testing, calculate non-HDL-C (total cholesterol minus HDL-C) from your standard lipid panel at no additional cost 2. This simple calculation captures all atherogenic particles (LDL, VLDL, IDL, and remnants) and predicts cardiovascular risk as well as or better than apoB in most patients 1, 3.
- Non-HDL-C is particularly valuable when triglycerides are ≥1.5 mmol/L (≥133 mg/dL), where LDL-C becomes unreliable 2
- Non-HDL-C >190 mg/dL (4.9 mmol/L) should be considered a risk-enhancing factor 1
- Can be measured fasting or non-fasting 2
Lipoprotein(a): The Most Important Advanced Test
Lp(a) is the single most valuable advanced lipid test beyond apoB because:
When to Measure Lp(a):
- Family history of premature ASCVD (males <55 years, females <65 years) 1, 4
- Early advanced atherosclerosis or premature cardiovascular events 1
- Unexpectedly poor LDL-C response to statins (statins don't lower Lp(a), but elevated Lp(a) contributes to measured LDL-C) 1
- Consider measuring once in all patients, potentially in early adulthood during routine screening 1
Key Characteristics:
- Genetically determined (>90% heritable), stable throughout life—measure only once 2, 1
- Not affected by fasting status, diet, or lifestyle 1
- Mendelian randomization studies confirm causal relationship with cardiovascular disease 2, 1
- Atherogenicity is approximately 7-fold greater than LDL on a per-particle basis 5
Interpretation:
- Elevated: ≥50 mg/dL or ≥125 nmol/L 1, 4
- Note: nmol/L values are roughly 2-3 times higher than mg/dL values 1
What NOT to Routinely Order
Multiple expert guidelines explicitly recommend against routine measurement of:
LDL Particle Size/Subfractions:
- No incremental predictive value beyond traditional risk factors 6
- The 2010 ACC/AHA guideline gives this a Class III: No Benefit recommendation 6
- While small, dense LDL particles are more atherogenic, measuring them adds little to clinical decision-making 1, 3
Direct LDL Particle Number (NMR):
- Shows similar associations to non-HDL-C without added benefit 6
- More expensive than calculated measures 3
Inflammatory Markers (Beyond Specific Indications):
- High-sensitivity CRP: Only useful in borderline/intermediate risk patients with LDL-C <130 mg/dL 7, 4
- Lipoprotein-associated phospholipase A2 (Lp-PLA2): Minimal reclassification benefit (<3% of patients) 8
Clinical Algorithm for Advanced Testing
Step 1: Calculate non-HDL-C from standard lipid panel (no additional cost)
Step 2: If triglycerides ≥1.5 mmol/L (133 mg/dL), use non-HDL-C or apoB instead of LDL-C for risk assessment and treatment targets 2
Step 3: Measure Lp(a) once if:
- Family history of premature ASCVD
- Personal history of premature atherosclerosis
- Unexplained cardiovascular events despite controlled LDL-C
- Consider universal screening once in early adulthood 1
Step 4: If discordance between apoB and non-HDL-C (8-23% of patients), apoB may be the better predictor 2
Step 5: In borderline/intermediate risk patients (10-year ASCVD risk 5-19.9%), consider coronary artery calcium score rather than additional lipid testing 1, 4
Important Caveats
The evidence is clear that advanced lipid testing adds minimal incremental risk prediction beyond standard lipids and non-HDL-C in the general population 1, 6, 1, 3. The 2020 Endocrine Society guideline explicitly states: "multiple expert panels and guidelines have concluded that these tests add little to risk prediction beyond the standard lipid profile" 1.
However, Lp(a) stands apart because:
- It identifies a genetically determined, independent risk factor
- It explains familial clustering of cardiovascular disease
- Specific therapies targeting Lp(a) are in development 1
- It helps explain residual risk in patients with well-controlled LDL-C
Recent research (2026) suggests emerging metrics like estimated small, dense LDL-C and the LDL-C/total cholesterol ratio may improve risk stratification 9, 10, but these are not yet incorporated into clinical guidelines and require validation before routine use.
The most cost-effective strategy remains: optimize use of standard lipid panel calculations (especially non-HDL-C), measure Lp(a) selectively, and reserve apoB for cases with elevated triglycerides or discordance with non-HDL-C 2, 4.